Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

FGFR2 as a molecular target in endometrial cancer.

Future oncology (London, England) - 1 Feb 2009

Byron Sara A, Pollock Pamela M

Abstract excerpt

Although molecularly targeted therapies have been effective in some cancer types, no targeted therapy is approved for use in endometrial cancer. The recent identification of activating mutations in fibroblast growth factor receptor 2 (FGFR2) in endometrial tumors has generated a new avenue for the development of targeted therapeutic agents. The majority of the mutations identified are identical to germline...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Clinical Trials as Topic
Share to Endometrial Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to FGFR2 gene

Share to FGFR3 gene

Share to Mutation

Share to Pyrimidines

Share to Receptor, Fibroblast Growth Factor, Type 2

Source

Identifiers

PMID: 19243295
DOI: 10.2217/14796694.5.1.27

Genes

FGFR2
FGFR3
KRAS
PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

FGFR2 as a molecular target in endometrial cancer.PMID 19243295Read ↗

Drug-sensitive FGFR2 mutations in endometrial carcinoma.Semantic proximity Read ↗

Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromesSemantic proximity Read ↗

Functional Distinctions of Endometrial Cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene.Semantic proximity Read ↗

Fibroblast growth factors and their receptors in cancer.Semantic proximity Read ↗

FGFR2 mutations promote endometrial cancer progression through dual engagement of EGFR and Notch signalling pathways.Semantic proximity Read ↗

Antitumor effects and molecular mechanisms of ponatinib on endometrial cancer cells harboring activating FGFR2 mutations.Semantic proximity Read ↗

Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.Semantic proximity Read ↗

Fibroblast growth factor receptor inhibition synergizes with Paclitaxel and Doxorubicin in endometrial cancer cells.Semantic proximity Read ↗

FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features.Semantic proximity Read ↗

Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation.Semantic proximity Read ↗

Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.Semantic proximity Read ↗

Future applications of FGF/FGFR inhibitors in cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.